Opioid Taper Practices Among Clinicians

Amelia L Persico,1,2 Jeffrey J Bettinger,2,3 Erica L Wegrzyn,2,4 Jeffrey Fudin,2,4 Scott A Strassels5,6 1Shields Health Solutions, Stoughton, MA, 02072, USA; 2Remitigate Therapeutics, Delmar, NY, 12054, USA; 3Saratoga Hospital Medical Group, Saratoga, NY, 12866, USA; 4Stratton VA Medical Center, Albany, NY, 12208, USA; 5The Ohio State University, Columbus, OH, 43004, USA; 6Atrium Health, Charlotte, NC, USCorrespondence: Amelia L Persico Email apersico@remitigate.comIntroduction: Opioid dose tapers are used frequently when cross-titrating from one or more opioids to another or when discontinuing therapy. Currently, there is no universally accepted evidence-based standard of care for this procedure which can leave patients at risk for withdrawal symptoms, inadequate pain control, or elevated suicide risk.Objective: The objective of this study was to examine practices and rationale among clinicians, to determine if there is a difference among respondents in their comfort level, method and rationale for tapering opioids at various morphine milligram equivalents (MME) and to assess the need for the development of a standard of care.Methods: Data were derived from an electronic survey developed using SurveyMonkey®. The survey was disseminated via e-mail listservs, social media, and professional organizations. Data were collected regarding profession, confidence tapering opioids at varying total MME, method and rationale for tapering, and pharmacologic management of withdrawal symptoms. Pearson’s Chi squared and Fisher’s exact tests were used to assess statistical significance of results.Results: A total of 149 clinicians completed the survey, physicians, NPs, pharmacists, and PAs accounted for 51%, 20%, 19%, and 10% of participants, respectively. Overall, 55% of the respondents self-identified as pain specialists. There were no statistically significant differences in reported comfort level among the different types of providers. Nearly 50% of participants indicated their rationale for tapering or discontinuing opioids was the 2016 CDC guidelines.Conclusion: Despite that the majority of providers surveyed self-identified as pain specialists, over 50% were not comfortable tapering opioids at doses greater than 120 MME/day. This observation suggests a need for further education and establishment of consensus guidelines on method and rationale for opioid tapering. Provider motivation for tapering was largely influenced by CDC guidelines based on low quality evidence. This strengthens the argument for the creation of guidelines based on high quality evidence.Keywords: opioid, pain management, chronic pai